

Pain Therapeutics

Drugs, Markets & Companies

By

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

June 2018

A Jain PharmaBiotech Report

A U T H O R ' S B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon by training and received graduate training in both Europe and US. He has held academic positions in several countries and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. During his active neurosurgical career, Prof. Jain was involved in the management of pain. He has been working in the biotechnology/biopharmaceuticals industry for several years and currently is the CEO at Jain PharmaBiotech.

Prof. Jain is an Associate Editor of MedLink Neurology, an electronic encyclopedia of neurology published by Medlink Corporation (San Diego, California) where he is also the author in charge of writing and yearly update of 161 articles including those on treatment of pain.

Prof. Jain's 476 publications include 30 books (6 as editor + 24 as author) and 50 special reports which have covered important areas in biotechnology, gene therapy and biopharmaceuticals. He has also written a textbook of gene therapy, which is the first book on this subject to be translated into the Chinese language. A book on gene therapy companies was published in 2000 by John Wiley & Sons and the updated version has been incorporated into a report on Gene Therapy published by Jain PharmaBiotech in 2014. Prof. Jain has edited "Drug Delivery Systems" (Humana/Springer 2008, 2nd ed 2014) and "Drug Delivery to the Central Nervous System" (Humana/Springer 2010). His other recent books include "Handbook of Nanomedicine" (Springer/Humana 2008; Chinese edition, Peking University Press 2011, 2nd ed Springer 2012, 3rd ed 2017), "Textbook of Personalized Medicine" (Springer 2009; Japanese ed 2012; 2nd ed Springer, 2015), "Handbook of Biomarkers" (Springer 2010; Chinese edition, Chemical Industry Press 2016, 2nd ed Springer, 2017), "Handbook of Neuroprotection" (Springer 2011, 2nd edn 2018, in preparation), "Applications of Biotechnology in Cardiovascular Therapeutics" (Springer 2011), "Applications of Biotechnology in Neurology" (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer 2014). He has edited "Applied Neurogenomics" (Springer 2015).

The pain report is an update with inclusion of commercial information in an earlier publication titled "Pain Therapeutics: A strategic re-evaluation" published by Reuter's Business Insight/Datamonitor UK in 2000. Other reports written by Prof. Jain in the past have been published by PJB Publications, D & MD, Informa, and Decision Resources Inc. This is one of the in-house publications of Jain PharmaBiotech that are constantly updated.

June 2018
Copyright ©2018 by

Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland

Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: http://pharmabiotech.ch/

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

0. Executive Summary	19
1. Basic Aspects of Pain	21
Introduction	21
Historical aspects of pain	21
Pain definitions	23
A glossary of terms relevant to pain	24
Pain classification and description	24
Neuropathic pain	25
<i>Refractory neuropathic pain</i>	26
<i>Classification of neuropathic pain according to levels</i>	26
Cancer pain	27
<i>Bone pain in cancer</i>	29
Complex regional pain syndrome	30
Mechanisms of pain	30
Pain pathways	31
<i>Role of nociceptors in pain transmission</i>	32
Gate control and neuromatrix theories of pain	32
Pain mediators	33
Modulation of pain by pictures associated with social contacts	34
Modulation of pain by emotions	34
Role of the sympathetic nervous system in pain	34
Visceral pain	35
<i>Pathomechanism of visceral pain</i>	35
Pathomechanism of neuropathic pain	35
<i>Role of intact nerve fibers in neuropathic pain</i>	35
<i>Chemokines as mediators of neuropathic pain</i>	36
<i>Chemotherapy-induced neuropathic pain</i>	36
<i>CNS innate immunity and neuropathic pain</i>	36
<i>Cytokines as mediators of neuropathic pain</i>	37
<i>Free radicals in generation of neuropathic pain</i>	37
<i>GABA deficiency in neuropathic pain</i>	37
<i>Genetic basis of neuropathic pain</i>	37
<i>Gene expression changes in neuropathic pain</i>	38
<i>Glial activation and neuropathic pain</i>	38
<i>Immune cell-derived opioids and neuropathic pain</i>	39
<i>Spinal leptin and neuropathic pain</i>	39
<i>Tetrahydrobiopterin regulates neuropathic pain sensitivity</i>	39
Pathomechanism of migraine	40
Role of the immune system in pain	41
Pain and itch	41
<i>Pathomechanism of itch</i>	41
<i>Clinical aspects of itch</i>	42
Molecular pathophysiology of pain	42
Role of ion channels in pain	43
<i>Acid-sensing ion channels</i>	43
<i>Calcium channels in pain</i>	43
<i>P2X3 ion channels</i>	44
<i>Potassium ion channels</i>	44
<i>Sodium ion channels in pain</i>	45
<i>TRP ion channels in pain</i>	46
Genetic basis of pain	47
<i>Alternative RNA splicing and pain</i>	47
<i>Study of genes in pain</i>	48
<i>Pain as a channelopathy</i>	48
Pain in the brain	49
<i>Effect of chronic pain on opioid receptors in the brain</i>	49
<i>Neuropathic pain-induced morphological changes in the brain</i>	49
Change from acute to chronic pain	50
<i>Acute versus chronic pain</i>	50
<i>Descending facilitatory modulation of pain</i>	50
<i>Development of chronic pain following severe accidental injury</i>	51
<i>Pain and transcriptional repressor DREAM</i>	51
<i>Role of neuronal plasticity in pain</i>	51
<i>Role of epigenetics in development of chronic pain</i>	52
<i>Concluding remarks on evolution of acute pain into chronic pain</i>	52
Neurochemistry of pain	52
<i>Molecular elements of pain in the peripheral nervous system</i>	52

<i>Molecular elements of pain in the central nervous system</i>	53
<i>Opioid receptors</i>	54
<i>Role of AMPA receptors in chronic pain</i>	54
<i>Kinins</i>	54
<i>Serotonin</i>	55
<i>Substance P</i>	55
<i>Excitatory amino acids</i>	56
<i>Role of nitric oxide in pain</i>	56
<i>Prostaglandins</i>	56
<i>Endocannabinoids</i>	58
<i>Protein kinase C</i>	58
<i>Adenosine and adenosine receptors</i>	58
<i>Vitamin D and pain</i>	59
<i>Vanilloid receptor</i>	59
<i>TRPA₁ and TRPV₁ receptors</i>	59
<i>Endothelin-B receptors</i>	61
<i>Nerve growth factor and pain</i>	61
<i>Adrenomedullin as a pain-related peptide</i>	61
Biomarkers of pain	62
<i>Biomarkers of visceral pain</i>	62
2. Assessment of Pain and Analgesics	63
Introduction	63
Animal models of pain	63
An overview	63
Selection of animal species as models for pain	63
Types of noxious stimuli	64
Animal models of neuropathic pain	64
Animal models of arthritis	64
Animal models of peripheral neuropathy	65
Limitations of current pain models	65
NeuroDigm GEL Model™ of neuropathic pain	66
Ethical issues concerning animal pain models	66
Medical evaluation of pain	67
Chronic pain as a manifestation of various diseases	67
Assessment of pain patients	67
Medical examination	67
Measurement of pain	68
Quality of pain intensity assessment in clinical research studies	69
Quantitative sensory testing	70
Pain measurement tools for neonates and children	70
Quantitative sensory testing	71
Microneurographic recordings	71
Psychological assessment of pain	72
Testing for in vivo pain processing	72
Brain imaging in pain	72
<i>fMRI for study of pain</i>	72
<i>PET for study of pain</i>	72
<i>PET correlated with fMRI and evoked potentials</i>	73
Patient outcomes and quality of life during treatment for chronic pain	73
Collection and analysis of data on pain patients	74
Evaluation of analgesics in humans	74
Early phase clinical trials of analgesics in humans	74
Design of clinical trials for pain	75
Assessment of neuropathic pain	76
Transdermal electrical stimulation for study of chronic pain	76
Placebo effect in pain	77
Role of electronic pain recording in determination of the placebo effect	77
Outcome measures for chronic pain trials	77
Pain, pain therapies and cognitive function	78
3. Pharmacotherapy of Pain	79
Introduction	79
Mechanism of action of currently used pain medications	79
Non-steroidal antiinflammatory drugs	80
COX-2 inhibitors	80
<i>Celecoxib</i>	81
<i>Metamizole</i>	82
<i>Nimesulide</i>	82
<i>Rofecoxib</i>	82
<i>Valdecoxib</i>	83

<i>Lumiracoxib</i>	83
<i>Side effects of COX inhibitors</i>	83
<i>Innovative COX-2 inhibitors in development</i>	85
Acetaminophen	86
Antioxidants as analgesics	86
Opiates and opioids	86
Morphine	87
Codeine	87
Tramadol	88
Innovations in opioid therapy	88
<i>Oral transmucosal fentanyl</i>	89
<i>Use of opioids for chronic non-cancer pain</i>	89
Opioid receptor modulation for visceral pain	89
Opiorphin	90
Sufentanil	90
N-methyl-D-aspartate receptor antagonists	90
Ketamine	90
CNS 5161	91
Triptans for treatment of non-migrainous pain	91
Capsaicin	92
NGX-4010	92
Local anesthetics	93
Topical application	93
Nerve blocks	93
<i>Injection of local anesthetics for analgesia</i>	93
<i>Ultrasound-guided nerve blocks</i>	93
Topical salicylates for the treatment of pain	94
Topical rubefacients for acute and chronic pain in adults	94
Adjunctive analgesics	94
Antidepressants	94
<i>Mechanism of analgesic action of antidepressants</i>	96
Antiepileptic drugs	96
<i>Mechanism of action of antiepileptic drugs in neuropathic pain</i>	97
<i>Carbamazepine</i>	98
<i>Gabapentin</i>	98
<i>Lamotrigine</i>	99
<i>Phenytoin</i>	99
<i>Pregabalin</i>	99
<i>Topiramate</i>	100
<i>Valproic acid</i>	101
<i>Other antiepileptic drugs</i>	101
Clonidine	101
Baclofen	101
Corticosteroids	102
Calcitonin	102
Bisphosphonates	103
Botulinum toxins	103
Analgesic effect of botulinum toxin A	103
Engineered botulinum toxin	104
Analgesics from traditional medical systems	104
Herbs and other plants	104
Analgesics derived from cobra toxin	105
4. Management of Pain	107
Introduction	107
Sites for pain management	107
Self-medication at home	107
Physicians' offices	107
Major hospitals	107
Pain centers	108
Non-pharmacological approaches to pain	108
Alternative medicine	108
<i>Acupuncture</i>	109
<i>Aromatherapy</i>	109
<i>Self-Controlled Energo Neuro Adaptive Regulation</i>	110
Behavioral therapy	110
<i>Cognition and pain</i>	110
<i>Control over brain activation and pain by using functional MRI</i>	110
<i>Mindfulness meditation for relief of chronic pain</i>	111
<i>Thermal-grill illusion</i>	111
<i>Virtual reality therapy</i>	111

Local application of heat	111
Transcutaneous nerve stimulation	112
Non-invasive brain stimulation techniques for chronic pain	112
<i>Transcranial magnetic stimulation</i>	112
<i>Cranial electrotherapy stimulation</i>	113
Neurosurgery for pain relief.....	113
<i>Ablative procedures on the nervous system</i>	113
<i>Procedures on peripheral, spinal and cranial nerves</i>	113
<i>Vagal nerve stimulation for control of pain</i>	114
<i>Neuromodulation</i>	114
<i>Spinal cord stimulation</i>	115
<i>Brain stimulation</i>	116
<i>Implantation of drug delivery devices</i>	117
Management of special types of pain	117
Acute pain	117
<i>Management of acute renal colic: NSAIDs vs. opioids</i>	117
<i>Combination of opioids and NSAIDs for acute pain</i>	118
<i>Reasons for inadequate management of acute pain</i>	118
Perioperative pain management.....	118
<i>Devices for delivery of analgesics in the postoperative period</i>	119
<i>Drug combination for perioperative pain</i>	120
<i>Gabapentin for reduction of postoperative pain</i>	120
<i>Ketamine for perioperative pain</i>	120
<i>Opioids for perioperative pain</i>	121
<i>Perioperative pain in neurosurgery</i>	121
<i>Prolonged duration local anesthesia</i>	122
<i>Concluding remarks on the management of postoperative pain</i>	122
Pain in the intensive care unit.....	123
Pain associated with sports and exercise.....	123
Pain associated with trauma.....	124
Chronic pain and sleep	124
Chronic abdominal pain	124
Functional somatic syndromes	125
Fibromyalgia syndrome.....	125
<i>Pathomechanism of FMS</i>	126
<i>Management of FMS</i>	126
<i>Non-pharmacological therapies for FMS</i>	126
<i>Pharmacotherapy of FMS</i>	127
<i>Concluding remarks on management of FMS</i>	128
Erythromelalgia	128
Irritable bowel syndrome	129
<i>Opioids for IBS</i>	130
<i>Pregabalin for IBS</i>	130
<i>Tricyclic antidepressants for IBS</i>	130
<i>Serotonin-modulating drugs for IBS</i>	130
Musculoskeletal pain	131
Myofascial pain syndrome	131
<i>Non-pharmacological methods of treatment of MPS</i>	131
<i>Pharmacotherapy of MPS</i>	132
Osteoarthritis	133
<i>Pain aggravates osteoarthritis by crosstalk between CNS and the joint</i>	134
<i>Management of osteoarthritis</i>	134
Rheumatoid arthritis.....	135
<i>Management of pain in rheumatoid arthritis</i>	136
<i>Disease modifying therapies in rheumatoid arthritis</i>	136
<i>Resurgence of interest in gold-based treatments for RA</i>	137
Backache and sciatica.....	138
<i>Lumbar disc disease and sciatica</i>	139
<i>Management of back pain with analgesics</i>	140
<i>Miscellaneous medical therapies for backache and sciatica</i>	141
Neck pain.....	141
Chronic pelvic pain.....	142
<i>Prostatitis</i>	142
Cancer pain.....	142
<i>Adjuvant drugs for cancer pain</i>	143
<i>Alternative non-pharmacological methods</i>	143
<i>Anesthetic techniques</i>	144
<i>Management of bone pain in cancer</i>	144
<i>Non-opioid analgesics for cancer pain</i>	144
<i>Opioid treatment of cancer pain</i>	144
<i>Opioid breakthrough pains</i>	146

<i>Opioid-induced enhancement of cancer growth and its prevention</i>	146
<i>Opioids delivery methods for cancer pain</i>	146
<i>Opioid administration through implanted drug delivery devices</i>	147
<i>Radiation therapy</i>	147
<i>Surgical methods of cancer pain relief</i>	148
<i>Conclusions regarding management of cancer pain</i>	148
Chronic non-malignant pain.....	148
Headache.....	149
<i>Cluster headache</i>	150
<i>Chronic daily headache</i>	150
<i>Indomethacin-responsive headache</i>	151
<i>Occipital neuralgia</i>	151
<i>Paroxysmal hemicrania</i>	152
<i>Tension headache</i>	152
Migraine.....	152
<i>Management of acute migraine</i>	153
<i>Chronic migraine</i>	156
<i>Pediatric migraine</i>	157
<i>Status migrainosus</i>	157
<i>Migraine prophylaxis</i>	158
<i>Non-pharmacological approaches to migraine</i>	159
Trigeminal neuralgia.....	160
Dental pain.....	161
Neuropathic pain.....	161
<i>Pathogenesis of neuropathic pain</i>	161
<i>Chronobiology of neuropathic pain as guide to therapy</i>	162
<i>Management of neuropathic pain based on mechanism</i>	162
<i>Guidelines for the management of neuropathic pain</i>	163
<i>Pharmacotherapy of neuropathic pain</i>	163
<i>Evidence-based management of neuropathic pain</i>	165
Management of central neuropathic pain.....	166
<i>Neurosurgical approaches to central neuropathic pain</i>	166
<i>Management of neuropathic pain in syringomyelia</i>	167
<i>Neuropathic pain associated with spinal cord injury</i>	167
Management of peripheral neuropathic pain.....	167
<i>Truncal neuropathic pain</i>	168
<i>Management of postsurgical peripheral neuropathic pain</i>	168
<i>Management of chemotherapy-induced pain</i>	168
<i>Morton's neuroma</i>	169
<i>Management of peripheral diabetic neuropathy</i>	169
<i>Postherpetic neuralgia</i>	171
<i>Treatment of complex regional pain syndrome</i>	173
<i>An algorithm for the management of peripheral neuropathic pain</i>	174
Phantom limb pain.....	175
<i>Pathomechanism of phantom limb pain</i>	175
<i>Management of phantom limb pain</i>	175
Painful neuromas following amputation.....	177
Pain and depression.....	178
<i>Neurochemical link between pain and depression</i>	178
<i>Management of chronic pain and depression</i>	179
Miscellaneous painful conditions.....	179
<i>Burning mouth syndrome</i>	179
<i>Chronic unstable angina</i>	180
<i>Mastalgia</i>	180
<i>Ophthalmic pain</i>	181
<i>Pain in Parkinson's disease</i>	181
Pain in sickle cell disease.....	181
Management of chronic unexplained pain.....	182
Management of itching.....	182
<i>Topical applications for itching</i>	183
<i>Systemic therapies for itching</i>	184
<i>Non-pharmacological therapies for itch</i>	184
Management of pain in special population groups.....	185
Racial and ethnic differences in pain management.....	185
Pain in neonates.....	185
Management of pain in children.....	185
<i>Misuse of codeine in children</i>	187
Management of pain in the elderly.....	187
Management of pain in women.....	188
<i>Reasons for increased pain perception in women</i>	188
<i>Chronic pelvic pain in women</i>	189

<i>Gender differences in response to analgesics</i>	189
<i>Considerations for pain management in women</i>	189
Management of pain in neurologically handicapped persons.....	190
Management of pain in the cognitively impaired elderly people.....	190
Management of pain in brain-damaged minimally conscious patients.....	191
Management of pain in the terminally ill.....	191
Problems in the management of pain	192
Inadequate pain management.....	192
Problems with use of opioids.....	192
<i>Guideline for use of opioids</i>	193
<i>Opioid regulations</i>	194
<i>Opioids alternatives</i>	194
Excessive prescription of gabapentinoids.....	195
<i>Problems with use of gabapentinoids</i>	195
Patterns of analgesic consumption in France vs other European countries.....	196
Suggestions for improvement of pain management by healthcare providers.....	196
<i>Management of neuropathic pain refractory to first line treatment</i>	198
<i>Multidisciplinary approaches to pain management</i>	198
<i>Pain as the fifth vital sign</i>	198
<i>Reassessment of management of chronic pain</i>	198

5. Drug Delivery for Pain	201
Introduction	201
Intra-articular injection for relief of joint pain	202
Delivery of analgesics to peripheral nerves	202
Controlled release drug delivery for pain	203
Accelerating the effect of subcutaneous morphine.....	203
Controlled drug delivery at site of pain.....	203
Oral extended release opioids.....	204
<i>Extended release oral morphine</i>	204
<i>Controlled release oxycodone</i>	204
<i>Extended release oxymorphone</i>	204
<i>Oral extended release tramadol</i>	205
Extended release gabapentin.....	205
Use of nanotechnology for drug delivery for pain.....	206
Non-injection methods of delivery of analgesics	206
Topical applications for pain.....	207
<i>Topical local anesthetics</i>	207
<i>Topical NSAIDs</i>	207
<i>Topical and transdermal diclofenac</i>	208
<i>Topical application for postoperative pain</i>	208
Needle-free drug delivery for pain.....	209
<i>Glide SDI® solid dose injector</i>	209
<i>SUMAVEL™ DosePro™ needle-less injection</i>	209
Transdermal drug delivery for pain.....	209
<i>Relief of pain associated with minor medical procedures</i>	209
<i>Transdermal fentanyl</i>	210
<i>Transdermal ketoprofen</i>	211
<i>Transdermal nitroglycerine as an adjuvant to opioids</i>	212
<i>Transdermal buprenorphine</i>	212
<i>Transdermal trans-capsaicin</i>	212
<i>Powder Injection Systems</i>	212
Intranasal delivery of analgesics.....	213
<i>Intranasal morphine</i>	213
<i>Intranasal morphine derivatives</i>	214
<i>Intranasal fentanyl</i>	215
<i>Intranasal buprenorphine</i>	215
<i>Intranasal ketamine</i>	215
<i>Intranasal ketorolac</i>	216
<i>Nasal formulations for migraine</i>	216
Oral spray formulations for migraine.....	216
Delivery of analgesics by inhalation.....	216
Buccal transmucosal and sublingual delivery of analgesics.....	217
<i>Application for cancer pain</i>	217
<i>Application for non-cancer pain</i>	218
Pumps for drug delivery in pain.....	218
<i>Patient controlled analgesia</i>	219
<i>Postoperative pain pumps</i>	219
<i>Chronogesic (sufentanil) Pain Therapy System</i>	220
<i>PatchPump</i>	221
Intrathecal delivery of analgesics	221

Anatomical & physiological aspects of intrathecal drug delivery	221
Pharmacokinetics of intrathecal drug delivery	223
Epidural drugs	223
<i>Pharmacokinetics of analgesic drugs following epidural injection</i>	223
<i>Epidural glucocorticoids</i>	224
<i>Epidural etanercept</i>	224
<i>Epidural morphine</i>	224
Intrathecal drugs	224
<i>Intrathecal adenosine</i>	226
<i>Intrathecal baclofen</i>	226
<i>Intrathecal fadolmidine</i>	226
<i>Intrathecal lidocaine</i>	227
<i>Intrathecal magnesium sulfate</i>	227
<i>Intrathecal midazolam</i>	227
<i>Intrathecal opioids</i>	227
<i>Intrathecal neostigmine</i>	228
<i>Intrathecal octeoride</i>	229
<i>Intrathecal non-NMDA antagonists</i>	229
<i>Intrathecal prostaglandin antagonists</i>	229
<i>Intrathecal resiniferatoxin</i>	229
<i>Intrathecal ziconotide</i>	230
Combinations of intrathecal agents for relief of pain	230
Pumps for intrathecal delivery of analgesics	231
Complications of intrathecal delivery of analgesics	231
Concluding remarks on intrathecal delivery of analgesic agents	232
Intracerebroventricular morphine for pain	232
Development of drug delivery systems for pain therapy	233
Delivery of analgesics to the CNS across the blood brain barrier	233
Drug delivery systems in clinical trials	233
6. Drug Development for Pain.....	237
Introduction	237
Drugs in development for pain.....	237
Current research goals	238
The ideal analgesic.....	238
Pain R & D goals in the pharmaceutical industry	238
Drug targets in the spinal cord	239
Drug targets in the brain	239
Molecular targets for analgesic drugs	239
Activation of P2X7 receptors.....	239
Alfa2-adrenergic receptor agonists	240
Angiotensin II type 2 receptor	240
Anti-NGF strategies	240
Bradykinin antagonists	240
Cannabinoids.....	241
<i>Cannabinoid receptor agonists</i>	242
<i>Cannabidiol</i>	244
<i>Cannabinor</i>	244
<i>Nabilone</i>	245
Capsaicin and VR1 receptor-based analgesics	245
<i>Vanilloid (capsaicin) receptor antagonists</i>	245
<i>VR1 receptor agonists</i>	246
CCR2 receptor blockade.....	246
Cholecystokinin antagonists	246
Cholinergic receptor agonists.....	246
Conotoxins as analgesics	247
Corticotropin-releasing factor	248
FAAH inhibitors.....	248
<i>PF-3845</i>	249
<i>URB597</i>	249
FKBP51 as a target for treatment of chronic pain	249
Free radical scavengers as analgesics.....	250
<i>Superoxide dismutase mimetics</i>	250
GABA analogs.....	250
<i>Subtype-selective GABAergic drugs</i>	251
Glutamate receptor antagonists	251
<i>NMDA receptor modulation for neuropathic pain</i>	251
<i>Alternatives to direct blocking of NMDA receptors</i>	252
<i>Glycine antagonists</i>	252
<i>Metabotropic glutamate receptors</i>	252
Histogranin-like compounds for the management of pain	253

Ion channels as targets for analgesic drugs	253
<i>Acid-sensing ion channels as drug target</i>	253
<i>Calcium channel blockers</i>	254
<i>HCN1 channels as targets for propofol analogs for neuropathic pain</i>	254
<i>P2X ion channel receptor antagonists</i>	255
<i>Sodium channel modulation</i>	255
Mas-related GPCR agonists.....	256
Microsomal prostaglandin E synthase inhibitors	256
NAALADase inhibitors	257
Neuropeptide receptor antagonists for improving the efficacy of opioids.....	258
Neurotrophic factor-based pain therapeutics.....	258
<i>Glial cell line-derived neurotrophic factor</i>	258
<i>Nerve growth factor antagonists</i>	258
Newer COX inhibitors	259
<i>COX-3 inhibitors</i>	259
<i>Dual cyclooxygenase/lipoxygenase inhibitors</i>	259
Nicotinic acetylcholine receptors	259
<i>Mode of action of nACh/neural nicotinic receptor agonists</i>	260
<i>Potential of central nACh/neural nicotinic receptor agonists</i>	260
Nitric oxide-based analgesics.....	261
<i>Nitric oxide-releasing NSAIDs</i>	261
<i>Pharmacology of NO-SAIDs</i>	262
<i>COX-inhibiting nitric oxide donors</i>	262
<i>NO-donating structures to extend life cycle of existing analgesics</i>	263
<i>Nitric oxide mimetics</i>	263
<i>Neuronal nitric oxide synthase inhibitors</i>	263
Norepinephrine transporter inhibition	263
Opioid peptide receptors ligands	264
<i>Buprenorphine</i>	265
<i>Nociceptin</i>	265
<i>Opioids with unique receptor characteristics</i>	265
<i>Tapentadol</i>	266
Opioid analgesics acting outside the CNS	266
<i>Oliceridine</i>	266
<i>Opioid analgesics acting at peripheral receptors</i>	267
<i>Peripherally acting mu-opioid receptor agonists</i>	267
<i>Targeting of opioid peptide-containing immune cells</i>	267
<i>Advantages of peripherally selective opioid drugs</i>	268
Resolvins	268
Somatostatin analogs	268
Substance P and neurokinin receptor antagonists.....	268
Substance P-Saporin	269
Targeting prostanoid synthesis	270
Tetrodotoxin based analgesics	270
TRPV1 modulators.....	271
<i>TRPV1 antagonists</i>	271
<i>TRPV1 agonists</i>	272
<i>TRPV1-mediated entry of sodium channel blocker QX-314</i>	272
<i>TRPV1 receptors regulate longevity</i>	273
Tumor necrosis factor- α antagonists.....	273
Biological therapies for pain	274
Cell therapy for pain	274
Cells for delivery of antinociceptive molecules	275
Cell therapy for low back pain.....	275
Cell therapy for knee pain due to degenerative disorders	276
Cell therapy for peripheral neuropathic pain	276
Cell transplantation for relief of pain.....	276
<i>Transplantation of chromaffin cells</i>	276
<i>Transplantation of stem cells</i>	277
<i>Transplantation of astrocytes secreting enkephalin</i>	277
<i>Transplantation of cells for relief of neuropathic pain</i>	277
Concluding remarks on cell therapy for pain	278
Gene therapy for pain	279
Rationale of gene therapy for pain	279
<i>Gene therapy of peripheral neuropathy</i>	279
<i>Gene therapy targeted to neuroimmune component of chronic pain</i>	280
Methods of gene delivery for pain	280
Vectors for gene therapy of pain	281
<i>Vectors for endogenous analgesic production in cranial neuralgias</i>	281
Methods of gene delivery for pain	282
<i>Gene delivery by intrathecal route</i>	282

Gene transfer to the dorsal nerve roots	282
Gene transfer by injections into the brain substance.....	283
Antisense therapy for pain	283
RNAi-based approaches for pain therapy.....	284
Potential applications of gene therapy for management of pain.....	285
Gene therapy for producing enkephalin to block pain signals	285
Gene therapy for upregulation of BMP in backache.....	287
Gene therapy for targeting nuclear factor- κ B.....	287
Gene therapy for neuropathic pain	287
Zinc finger DNA-binding protein therapeutic for chronic pain	288
Concluding remarks about gene therapy for pain	288
Preclinical development of pain drugs	289
NGF-blocking antibody.....	289
Prostatic acid phosphatase as a novel analgesic.....	290
Preclinical development of drugs for neuropathic pain.....	290
5-HT receptor agonists	291
A-803467.....	291
α 9 α 10 antagonists	291
AM1241	292
Artemin/Neuroblastin	292
Capsazepine.....	293
Central nACh receptor agonists.....	293
CGP 35024.....	293
Cortistatin.....	294
Drugs that suppress glial activation.....	294
Erythropoietin.....	295
NO donating GABA-agonist drugs.....	295
Resiniferatoxin.....	295
Targeting tumor necrosis factor	296
Future targets for osteoarthritic pain	296
Pain drugs in clinical trials.....	296
Clinical trials of miscellaneous drugs for pain.....	297
Alvimopan.....	298
Asimadoline	299
EN3202	299
Oxytrex	299
Drugs in clinical trials for postsurgical pain	300
Bicifadine.....	300
DepoMorphine	301
Cox-2 inhibitors in clinical trials	302
Clinical trials of disease modifying therapies for arthritis	302
Drugs in clinical development for neuropathic pain.....	304
Adenosine A1 agonists for neuropathic pain	306
Ajulemic acid.....	307
AVP-923 (dextromethorphan + quinidine).....	307
Botulinum toxin type A	307
Carisbamate.....	308
CNV1014802	308
D-amino acid oxidase inhibitors	308
Glyx-13	308
IP-751	309
Lacosamide.....	309
Oxcarbazepine.....	309
Perampanel.....	309
Ralfinamide.....	310
Retigabine.....	310
SB-509.....	310
TC-6499	310
Tebanicline.....	311
Tezampanel	311
Thalidomide	311
TRO19622.....	312
V3381 (indantadol)	312
XP-13512.....	312
Zonisamide	313
Drug discovery and development for migraine	313
Drugs in clinical development for treatment of migraine.....	313
Clinical development of preventive therapies for migraine	317
Monoclonal antibodies targeting CGRP for migraine prophylaxis.....	317
Drug development for visceral pain	318

7. Safety, Regulatory and Legal issues of pain management	321
Safety issues of analgesics	321
Adverse effects of analgesics	321
Gastrointestinal adverse effects of NSAIDs.....	321
<i>Measures to reduce gastrointestinal adverse effects of NSAIDs</i>	<i>321</i>
Cardiovascular adverse effects of COX-2 inhibitors.....	321
Adverse effects of opioids	322
<i>Addiction and development of tolerance.....</i>	<i>322</i>
<i>Chronic pain and opioid addiction.....</i>	<i>323</i>
<i>Abuse-deterrent opioid products</i>	<i>324</i>
<i>Problems and limitations of abuse-deterrent opioids.....</i>	<i>325</i>
<i>Complications of opioid abuse in the elderly</i>	<i>326</i>
<i>Hyperalgesia associated with opioids</i>	<i>326</i>
<i>Narcotic bowel syndrome</i>	<i>327</i>
<i>Opioid use disorder</i>	<i>327</i>
<i>Opioid withdrawal</i>	<i>328</i>
<i>Opioid-associated constipation.....</i>	<i>328</i>
<i>Respiratory depression</i>	<i>328</i>
Role of opioid prescribing patterns of physicians	328
Adverse effects of use of opioids in non-malignant pain	329
<i>Pharmacogenetics of adverse effects of codeine.....</i>	<i>329</i>
<i>PEGylated naloxol</i>	<i>330</i>
<i>Innovative approaches to modify opioid pharmacology</i>	<i>330</i>
Adverse effects of miscellaneous non-narcotic analgesics	330
<i>Adverse effects of immunosuppressants used for relief of pain.....</i>	<i>330</i>
<i>Adverse effects of acetaminophen</i>	<i>331</i>
<i>Hyponatremia as an adverse effect of tramadol</i>	<i>331</i>
Regulatory issues	331
Opioids.....	331
DEA and use of opioids for pain relief in terminal care	331
Cannabinoids.....	332
FDA and COX-2 inhibitors.....	332
Legal issues of COX-2 inhibitors	333
Regulatory aspects of opioid safety and abuse	333
Opioid misuse and regulatory agencies	333
FDA measures for safety of opioid use	334
Misuse of fentanyl	335
Regulation of extended release and long-acting opioids	335
Pain relief as a legal right	337
Pain relief and the WHO.....	337
8. Pain Markets.....	339
Introduction	339
Epidemiological basis of pain markets	339
Cancer.....	340
Neuropathic pain.....	340
Trigeminal neuralgia.....	340
Arthritis	340
Backache	340
Migraine	341
Multiple sclerosis.....	341
Irritable bowel syndrome	341
Chronic pelvic pain.....	341
Chronic pain due to traumatic brain injury	341
Postsurgical pain.....	342
Economics of pain	342
Pain as a driver of healthcare costs	342
Disability and financial loss through pain.....	343
Pain markets based on painful conditions.....	343
The cancer pain market	343
The arthritis pain market	344
Postsurgical pain market.....	344
The backache market	344
The headache market.....	345
Neuropathic pain market.....	345
Fibromyalgia market	346
Pain markets based on drugs.....	346
Opioids.....	346
Nonsteroidal antiinflammatory drugs	347
Transdermal pain therapeutics.....	347
Anesthesia	347

Antiepileptic drugs as analgesics	348
Other drugs.....	348
Hospital vs retail share of pain market.....	348
<i>Hospital versus retail opioid market.....</i>	<i>348</i>
Devices for pain.....	348
Pain markets according to geographical areas.....	349
Cost effectiveness of various approaches	349
Unfulfilled R&D needs in pain therapy	350
Under treatment of pain	350
Unfulfilled needs in drug development for chronic pain	350
Strategies for developing pain markets	351
Finding alternatives to intrathecal administration for chronic pain	351
Development of other applications of analgesic drugs.....	351
Partnership of patients, pharmacists and companies.....	352
Factors that may influence future pain markets	352
Drivers of pain markets	352
Public surveys as indicators of impact of pain on people.....	353
Effect of regulatory reviews on markets for pain products	353
Novel versus older therapies for pain.....	354
9. Future of Pain Therapeutics.....	355
Introduction	355
Advances in the understanding of pain	355
Pathogenesis of chronic pain	355
Role of glia in neuropathic pain.....	355
Molecular and neurobiological techniques.....	356
Improved understanding of cancer pain	357
Advances in drug discovery and development for pain	357
Novel targets for drug discovery for pain	357
<i>PTH2 receptor</i>	<i>357</i>
<i>Modulators of endogenous cannabinoids</i>	<i>358</i>
Application of new technologies to pain therapeutics	358
<i>Application of nanobiotechnology to pain therapeutics</i>	<i>359</i>
<i>Technologies for the manufacture of analgesics</i>	<i>360</i>
Future trends and needs in pain management.....	360
Pain management in future healthcare systems	361
Systems biology approach to pain	361
Personalized management of pain	362
Genetic factors in response to pain.....	363
Genetic mutations with loss of pain	364
Genetic mutations and painful conditions	364
Mechanism-specific management of pain	364
Pharmacogenomics and pharmacogenetics of pain	365
Personalized management of pain with commonly used analgesics.....	365
<i>Pharmacogenomics and pharmacogenetics of opioids</i>	<i>365</i>
<i>Pharmacogenetics of NSAIDs.....</i>	<i>366</i>
Preoperative testing to tailor postoperative analgesic requirements.....	367
Role of conditioned pain modulation in personalized management of pain	367
Signature of pain on brain imaging.....	367
Strategies for improving pain management.....	368
Research on pain in Europe	368
10. Companies Involved in Pain Therapeutics.....	371
Introduction	371
Profiles of companies.....	371
Collaborations.....	551
11. References.....	557

Tables

Table 1-1: Landmarks in the history of pain therapeutics.....	22
Table 1-2: Classification of pain.....	24
Table 1-3: Classification of neuropathic pain	26
Table 1-4: Classification of chronic cancer pain according to cause.....	28
Table 1-5: Percentage of patients with pain according to the type of cancer	29
Table 1-6: Key molecular elements of pain in the peripheral nervous system	53
Table 1-7: Key molecular elements of pain in the central nervous system.....	53
Table 2-1: IASP guidelines for the use of animals in pain studies	66

Table 2-2: Chronic pain as a manifestation of other diseases.....	67
Table 2-3: Recommendations for assessing patient satisfaction with pain management.....	73
Table 3-1: Classification of some currently used pain medications according to mechanism.....	79
Table 3-2: Drugs used for the treatment of pain.....	79
Table 3-3: Selective COX-2 inhibitors in clinical use for pain.....	81
Table 3-4: Antiepileptic drugs with analgesic effect.....	96
Table 4-1: Non-pharmacological approaches to management of pain.....	108
Table 4-2: Companies involved in neuromodulation therapy for pain.....	114
Table 4-3: Reasons for the inadequate management of acute pain.....	118
Table 4-4: Monoclonal antibodies as disease modifying therapies in rheumatoid arthritis.....	136
Table 4-5: Causes of chronic backache.....	139
Table 4-6: Management of chronic pelvic pain.....	142
Table 4-7: Management of pain in cancer.....	143
Table 4-8: Definitions of tolerance, physiological dependence, withdrawal and addiction.....	149
Table 4-9: A simplified classification of headache.....	149
Table 4-10: Various methods for the management of acute migraine.....	153
Table 4-11: Prophylaxis and management of chronic migraine.....	156
Table 4-12: Evidence-based level of choice of drugs for prophylaxis of migraine.....	158
Table 4-13: Management of neuropathic pain based on mechanism and diagnosis.....	163
Table 4-14: Management of central neuropathic pain.....	166
Table 4-15: Current management of peripheral diabetic neuropathy.....	169
Table 4-16: Treatment strategies for postherpetic neuralgia.....	171
Table 4-17: Management of complex regional pain syndrome.....	173
Table 4-18: Methods of treating phantom limb pain.....	175
Table 4-19: Treatment of chronic unexplained pain due to central sensitization.....	182
Table 4-20: Anti-itching therapies.....	182
Table 4-21: Suggested improvements in the management of pain.....	197
Table 5-1: A classification of drug delivery methods used in management of pain.....	201
Table 5-2: Selected marketed non-injection drug delivery systems for pain.....	206
Table 5-3: Approved drugs for spinal administration for pain.....	224
Table 5-4: Off-label intrathecal use of drugs for for pain.....	225
Table 5-5: Experimental studies of intrathecal administration of drugs for analgesia.....	225
Table 5-6: Intrathecal drugs for pain in clinical trials.....	225
Table 5-7: Comparison of pharmacokinetics of lipophilic with hydrophilic opioids.....	227
Table 5-8: Delivery systems for pain (other than intrathecal) in clinical development.....	234
Table 6-1: Classification of drugs in development for pain.....	237
Table 6-2: Preclinical studies on cannabinoid (CB2) receptor agonists as analgesics.....	243
Table 6-3: Cannabinoid receptor agonists in clinical development as analgesics.....	243
Table 6-4: NO-related therapies for pain.....	261
Table 6-5: Major opioids receptors and their ligands.....	264
Table 6-6: Strategies to counteract pain at various levels at periphery and in the CNS.....	270
Table 6-7: Types of TRPV1 antagonists.....	271
Table 6-8: TRPV1 antagonists in clinical trials.....	272
Table 6-9: Biological therapies for pain.....	274
Table 6-10: Experimental gene therapy approaches for relief of pain.....	280
Table 6-11: Selected preclinical approaches to pain therapy.....	289
Table 6-12: Selected preclinical drugs for neuropathic pain.....	290
Table 6-13: Selected clinical trials of miscellaneous drugs for pain.....	297
Table 6-14: Selected clinical trials of drugs for postsurgical pain.....	300
Table 6-15: COX-2 inhibitors in clinical development.....	302
Table 6-16: Disease modifying drugs for arthritis in clinical trials.....	302
Table 6-17: Clinical trials of drugs for neuropathic pain.....	304
Table 6-18: Selected drugs in clinical development for migraine.....	313
Table 6-19: CGRP receptor antagonists in clinical development for acute migraine.....	315
Table 6-20: Clinical trials of anti-CGRP monoclonal antibodies for migraine prevention.....	318
Table 6-21: Therapeutic targets for treating visceral pain.....	319
Table 7-1: Abuse-deterrent opioid products.....	325
Table 7-2: Diagnostic criteria for an opioid-use disorder.....	327
Table 8-1: Market values for various painful conditions 2017-2027.....	343
Table 8-2: Changes in market shares of drugs for neuropathic pain 2017-2027.....	345
Table 8-3: Markets for pain according to therapies 2017-2027.....	346
Table 8-4: Distribution of value of pain therapeutics in major markets 2017-2027.....	349
Table 8-5: Distribution of value of opioids in major pain markets 2017-2027.....	349
Table 8-6: Distribution of value of NSAIDs in major pain markets 2017-2027.....	349
Table 8-7: Strategies for developing pain markets.....	351
Table 9-1: P450 isoforms in the metabolism of drugs used in the management of pain.....	365
Table 10-1: Top companies in pain therapeutics.....	371
Table 10-2: Product pipeline of Adolor Corporation.....	378
Table 10-3: Selected collaborations in the area of pain management.....	551

Figures

Figure 1-1: Afferent pain pathways	31
Figure 1-2: Evolution of the gate control theory	33
Figure 1-3: The body self-neurometric.....	33
Figure 1-4: Various ligands and receptors on the peripheral terminals of nociceptive nerve fibers	53
Figure 1-5: Prostaglandin biosynthesis pathway	58
Figure 2-1: Biopsychosocial factors that interact and modulate the experience of pain.....	68
Figure 2-2: Pain intensity scales	69
Figure 3-1: Pathway of metabolism of codein	88
Figure 4-1: The WHO step ladder for pain	145
Figure 4-2: An algorithm for the acute management of migraine	154
Figure 4-3: Neuroimmune activation events leading to sensitization of CNS	162
Figure 4-4: An algorithm for the management of peripheral neuropathic pain.....	174
Figure 4-5: Algorithm for management of patients with chronic pain and depression.....	179
Figure 5-1: Powder Injection Systems	213
Figure 5-2: Penetration of CSF into spinal cord	222
Figure 5-3: Disposition of opioids after intrathecal administration	223
Figure 6-1: Attributes of the ideal analgesic	238
Figure 6-2: Nerve targeting drug delivery system for gene therapy of pain	286
Figure 8-1: Unfulfilled needs in the treatment for chronic pain.....	350
Figure 9-1: Impact of new technologies on pain therapeutics	359
Figure 9-2: Essential components of personalized management of pain	362
Figure 9-3: Genetic and non-genetic factors affecting efficacy and side effects of opioids.....	366